# US 2024/0199628 A1 · Tetrapyrrole-based compounds and their fomulations for anti-microbial therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199628 A1
- Document ID: US20240199628A1
- Status: Published application
- Kind: A1
- Application number: 18/295,582
- Filed: 2023-04-04
- Published: 2024-06-20
- Earliest claimed: 2021-10-05
- Assignees: Biolitec Unternehmensbeteiligungs II AG; Fraunhofer Gesellschaft zur Foerderung der AF EV
- Applicants: biolitec Unternehmensbeteiligungs II AG; Fraunhofer Gesellschaft zur Foerderung der AF EV
- Inventors: Volker Albrecht; Hagen Von Briesen; Dietrich Scheglmann; Burkhard Gitter; Arno Wiehe; Sylvia Wagner; Anja Germann; Dorika STEEN; Gerhard Wieland
- Web page: https://patentgrep.com/patent/US20240199628A1

## CPC

- C07D 487/22: in which the condensed system contains four or more hetero rings
- A61K 31/315: Zinc compounds
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- C07F 3/06: Zinc compounds
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Biologically active compounds are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for phototherapy, including photodynamic therapy, of viral or bacterial infections. As the compounds exhibit also toxicity against targets (bacteria, viruses) without light these biologically active compounds may also be used for the light-independent treatment of such diseases. Embodiments include porphyrins, chlorins, and dihydroxy chlorins as well as their zinc complexes. Also included are embodiments where these compounds are incorporated into liposomal formulations.

## Claims

### Claim 1

A tetrapyrrole compound based on the formulas 1, 2 or 3:

### Claim 2

A tetrapyrrole zinc complex based on the formulas 4, 5 or 6:

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antimicrobial therapy.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antibacterial therapy.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antiviral therapy.

### Claim 6 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antiviral therapy against enveloped viruses.

### Claim 7 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in photodynamic therapy against bacteria or viruses.

### Claim 8 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in photodynamic therapy against enveloped viruses.

### Claim 9 (depends on 1, 2)

The compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antiviral therapy against AIDS, Dengue fever or Covid-19.

### Claim 10 (depends on 1, 2)

A pharmaceutical formulation of a compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antibacterial therapy.

### Claim 11 (depends on 1, 2)

A pharmaceutical formulation of a compound of claims 1 and 2 or a pharmaceutically acceptable derivative thereof for use in antiviral therapy.

### Claim 12 (depends on 1, 2)

A pharmaceutical formulation of a compound of claims 1 and 2 or a pharmaceutically acceptable derivative thereof for use in antiviral therapy against enveloped viruses.

### Claim 13 (depends on 1, 2)

A lipid-based pharmaceutical formulation of a compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof for use in antiviral therapy against retroviridae (e.g. HIV), coronaviridae (e.g. SARS-COV-1, SARS-COV-2, MERS-COV) or flaviviridae (e.g. Dengue virus).

### Claim 14 (depends on 1, 2)

A compound of claim 1 or 2 or a pharmaceutically acceptable derivative thereof when loaded onto a surface of a medical device.
